Metagenomi, Inc. ( (MGX) ) has issued an update.
Metagenomi, Inc. reported its full-year 2024 financial results and business updates, highlighting significant progress in its genetic medicine programs. The company declared a development candidate for hemophilia A, demonstrated sustained Factor VIII activity in nonhuman primates, and advanced its Ionis collaboration in cardiometabolic indications. With a strong cash position of $248.3 million, Metagenomi is well-capitalized to support its operations into 2027, aiming to file IND submissions in 2026 for its hemophilia A program and continue advancing its pipeline.
More about Metagenomi, Inc.
Metagenomi, Inc. is a precision genetic medicines company that focuses on developing curative therapeutics using its AI-driven metagenomics platform. The company leverages the study of genetic material from the environment to discover and develop novel genome editing tools capable of correcting genetic mutations across the genome. Its toolbox includes programmable nucleases, base editors, and integration systems, positioning Metagenomi to unlock the full potential of genome editing for patients.
YTD Price Performance: -48.81%
Average Trading Volume: 1,103,798
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $72.6M
See more data about MGX stock on TipRanks’ Stock Analysis page.